Pharmaceutical News

RSS

Form of baclofen works better at treating narcolepsy

Neuroscientists at SRI International have found that a form of baclofen, a drug used to treat muscle spasticity, works better at treating narcolepsy than the best drug currently available when tested in mice.

8 May 2014

Researchers create universal flu vaccine

Researchers at the University of Texas Medical Branch are working to create a universal flu vaccine - one that could eliminate the need for an annual flu shot.

8 May 2014

Systagenix introduces hydro-active dressing in UK and Germany

Systagenix announced today the launch of BIOSORB™, a hydro-active dressing containing superabsorbent fluid-retaining polymers.

7 May 2014

Scientists develop gel based eye fluid to help stabilize eye after retinal detachment surgery

In an effort to avoid serious side effects suffered after surgery to repair retinal detachment, vision scientists have developed a new product to help stabilize the eye while it heals.

7 May 2014

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

AstraZeneca today announced the US Food and Drug Administration (FDA) approved EPANOVA (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia (triglyceride levels greater than or equal to 500 mg/dL).

7 May 2014

Novel bioinformatics approach suggests antimicrobial drug may help in treating advanced kidney cancer

Developing and testing a new anti-cancer drug can cost billions of dollars and take many years of research.

6 May 2014

FDA accepts Merck's MK-3475 BLA for review

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application (BLA) for MK-3475, Merck's investigational anti-PD-1 antibody, for the treatment of unresectable or metastatic melanoma in patients who have been previously treated with ipilimumab.

6 May 2014

Kinex receives FDA allowance for Oratecan anti-cancer drug irinotecan with enhanced oral absorption

Kinex Pharmaceuticals, Inc. announced today that the United States Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) application for Oratecan, an oral form of an approved anti-cancer drug irinotecan with enhanced oral absorption.

6 May 2014

Compound Formula Rehmannia reduces levodopa-induced dyskinesia in Parkinson's disease

Levodopa is the preferred treatment for Parkinson's disease in the clinic. However, long-term use of levodopa may lead to various motor complications, among which levodopa-induced dyskinesia is the most common, severely affecting patients' quality of life.

6 May 2014

Rates of infant immunization with pertussis-containing vaccine do not increase with epidemic

Conventional wisdom holds that when the risk of catching a disease is high, people are more likely to get vaccinated to protect themselves.

6 May 2014

Teva's SYNRIBO for injection receives FDA approval for home administration

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous use, to include home administration, and also approved a related Medication Guide and Instructions for Use.

6 May 2014

Compounds in soy sauce can be 70 times more potent than first-line HIV drug Tenofovir

For HIV patients being treated with anti-AIDS medications, resistance to drug therapy regimens is commonplace. Often, patients develop resistance to first-line drug therapies, such as Tenofovir, and are forced to adopt more potent medications.

6 May 2014

High-dose steroid therapy following surgery do not improve bile drainage among infants

Among infants who underwent surgery to repair bile ducts that do not drain properly (biliary atresia), the administration of high-dose steroid therapy following surgery did not significantly improve bile drainage after 6 months, although a small clinical benefit could not be excluded, according to a study in the May 7 issue of JAMA, a theme issue on child health.

5 May 2014

High doses of steroids fail to improve outcomes in pediatric liver disease

A multi-center study concludes that treating infants with high doses of steroids fails to improve medical outcomes in the end-stage pediatric liver disease biliary atresia and leads to earlier onset of serious adverse events.

5 May 2014

Vibrating oral capsule for chronic constipation shows positive results

An oral capsule that vibrates as it moves through the digestive tract has shown notable promise as a non-pharmacological treatment for constipation, according to new research presented today at Digestive Disease Week- (DDW).

5 May 2014

Trends, opportunities and threats in the life science industry: an interview with Bob Coughlin, CEO, MassBio

We were extremely excited to launch the Impact 2020 report at our annual meeting. Our five-year strategic plan is focused on value, early-stage financing and ensuring more patient-centered discussions.

5 May 2014

FDA grants Orphan Drug Designation to Advaxis' ADXS-HPV for treatment of invasive cervical cancer

Advaxis, Inc., a leader in developing cancer immunotherapies, announced today that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration Office of Orphan Products Development (OOPD) for ADXS-HPV, its lead immunotherapy drug candidate, for the treatment of Stage II-IV invasive cervical cancer.

2 May 2014

Ruthigen files IND Application to FDA for lead drug candidate RUT58-60

Ruthigen, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, today announced that the Company has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration for its lead drug candidate RUT58-60.

2 May 2014

Acorda gets FDA Complete Response Letter for PLUMIAZ Nasal Spray NDA

Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for PLUMIAZ (diazepam) Nasal Spray for the treatment of people with epilepsy who experience cluster seizures.

2 May 2014

New findings show combination of statins and omega-3 fatty acid may potentially reduce cardiovascular risk

New findings from an in vitro study, led by researchers at Brigham and Women's Hospital (BWH), show that the combination of statins and eicosapentaenoic acid (EPA), an omega-3 fatty acid, may potentially reduce cardiovascular risk.

2 May 2014

Pharmaceutical News

Form of baclofen works better at treating narcolepsy

Researchers create universal flu vaccine

Systagenix introduces hydro-active dressing in UK and Germany

Scientists develop gel based eye fluid to help stabilize eye after retinal detachment surgery

AstraZeneca’s EPANOVA receives FDA approval for treatment of adults with hypertriglyceridemia

Novel bioinformatics approach suggests antimicrobial drug may help in treating advanced kidney cancer

FDA accepts Merck's MK-3475 BLA for review

Kinex receives FDA allowance for Oratecan anti-cancer drug irinotecan with enhanced oral absorption

Compound Formula Rehmannia reduces levodopa-induced dyskinesia in Parkinson's disease

Rates of infant immunization with pertussis-containing vaccine do not increase with epidemic

Teva's SYNRIBO for injection receives FDA approval for home administration

Compounds in soy sauce can be 70 times more potent than first-line HIV drug Tenofovir

High-dose steroid therapy following surgery do not improve bile drainage among infants

High doses of steroids fail to improve outcomes in pediatric liver disease

Vibrating oral capsule for chronic constipation shows positive results

Trends, opportunities and threats in the life science industry: an interview with Bob Coughlin, CEO, MassBio

FDA grants Orphan Drug Designation to Advaxis' ADXS-HPV for treatment of invasive cervical cancer

Ruthigen files IND Application to FDA for lead drug candidate RUT58-60

Acorda gets FDA Complete Response Letter for PLUMIAZ Nasal Spray NDA

New findings show combination of statins and omega-3 fatty acid may potentially reduce cardiovascular risk

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News